BRAF and neoplasm: At the same time, no significant association is known between PFS duration and other clinical factors including primary tumor localization, BRAF gene mutation status, stage at treatment start, presence of CNS or liver metastases, type of prior therapy, or response to first-line (ipilimumab) therapy if used in the second-line, as in the case of our analysis (Table 2) [31,33].